Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
store icon
10mlGas/LiquidSyringewithAdjustablePlungerandremovable2"X#22needle – Repligen
10 ml Gas/Liquid Syringe with Adjustable Plunger and removable 2" X #22 needle
store icon
50mlGas/LiquidSyringewithAdjustablePlungerandremovable2"X#22needle – Repligen
50 ml Gas/Liquid Syringe with Adjustable Plunger and removable 2" X #22 needle
store icon
5mlGas/LiquidSyringewithAdjustablePlungerandremovable2"X#22needle – Repligen
5 ml Gas/Liquid Syringe with Adjustable Plunger and removable 2" X #22 needle
external link icon
Repligen Announces Agreement to Acquire Avitide Inc.
Proposed acquisition strengthens Repligen’s Proteins business Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH Strategically moves Repligen into affinity resin solutions for gene therapy Avitide is expected to contribute approximately $10 million in revenue in 2022 and be accretive to Repligen’s adjusted earnings per share in 2023 WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines. Tony
external link icon
Repligen Added to the Russell 2000 Index
Repligen Corporation (NASDAQ:RGEN) today announced that the Company’s stock has been added to the Russell 2000 ® index, a subset of the Russell 3000 ® and the Russell Global ® indexes. Russell Investments’ annual index reconstitution was finalized on June 22, 2012. The Russell indexes are widely used by investment managers and institutional investors as proxies for asset allocation and as performance benchmarks for investment strategies. “We are pleased that Repligen has been added to the Russell 2000 index, and believe that our inclusion will enhance our visibility among institutions that rely on equity indexes as part of their investment strategy,” stated Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 is a subset of the Russell 3000 Index and is constructed to provide a comprehensive and unbiased small-cap barometer. It is reconstituted
external link icon
Repligen to Present at Upcoming Investor Conferences
publications icon
ISO 13485:2016 Certificate of Certification - US (Irving)
corporate icon
XCell® ATF Systems
Simplify and intensify upstream bioprocessing. The XCell® ATF System, in single-use or stainless steel format, delivers high cell retention. High impact upstream solutions include N-1 perfusion, high productivity harvest, long-term perfusion and seed train intensification.
publications icon
EN ISO 13485:2016 Certificate of Certification - US (Irving)
corporate icon
KlariFi™ Software
KlariFi™ is an intuitive, end-to-end recipe-driven automation software for downstream bioprocessing professionals using Repligen systems for filtration or chromatography.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support